Cellestia Biotech AG

Developing First-in-Class therapies for cancer and AIIDs.

Swiss Startup - Cellestia Biotech Main Image

Cellestia is a clinical-stage biopharma led by an experienced team of scientists, drug developers and business professionals.

VISION

Cellestia is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders.

MISSION

Develop CB-103, a novel, first-in-class, oral pan-NOTCH inhibitor with a unique mode of action for treatment of NOTCH dependent leukemias, lymphomas and solid tumors.

HISTORY

Cellestia Biotech AG was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne, Switzerland). Cellestia`s pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decade

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

14.04.2025

Cellestia Biotech spins-off Anciata Therapeutics (startupticker.ch)

05.11.2024

Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)

31.05.2024

Swiss life science startups headed for San Diego (startupticker.ch)

06.05.2024

Innosuisse funded 45 Start-up innovation projects (startupticker.ch)

06.11.2023

A decent representation at BIO-Europe (startupticker.ch)

03.07.2023

Swissnex San Francisco Propel Swiss Health Startups into the US Market (startupticker.ch)

10.03.2022

Fourteen Swiss startups ready for scaling (startupticker.ch)

23.08.2021

Cellestia Biotech receives investment to advance first-in-class therapies to control and modulate pathogenic gene expression (venturelab.swiss)

17.08.2021

Cellestia Biotech attracts first investment of SNGLR Capital (startupticker.ch)

12.03.2021

Cellestia - a leading pioneer in modulating gene expression has received the Innosuisse Certificate (startupticker.ch)

20.10.2020

Cellestia presents promising clinical data of its lead compound (startupticker.ch)

14.09.2020

Strong Swiss delegation at Bio Europe (startupticker.ch)

10.08.2020

An almost complete C-suite for Swiss startups (startupticker.ch)

19.05.2020

Eleven Swiss start-ups on the virtual BIO Digital stage (startupticker.ch)

10.02.2020

Five Swiss health-tech startups head to BioAsia2020 (startupticker.ch)

17.12.2019

Cellestia Biotech AG Raises CHF 20M to Finance Clinical Trial of its Gene Transcription Cancer Therapy (venturelab.swiss)

17.12.2019

Cellestia Biotech raises CHF 20 million a series B round (startupticker.ch)

16.12.2019

IMD Startup competition reveals the winners of the 2019/2020 edition (startupticker.ch)

04.11.2019

Cellestia Biotech wins Sino-Swiss Business Awards (startupticker.ch)

16.04.2019

?1.2 million to accelerate time to market (startupticker.ch)

Last Tweets

Tweets by TwitterDev

No milestones

No Jobs

Documents

venture leaders 2013 Public profile

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

TOP 100 Swiss Startups 2019 TOP 100 Swiss Startups 2018 TOP 100 Swiss Startups 2017 TOP 100 Swiss Startups 2016

Website

Venture Leaders Technology

The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.

«venture leaders» 2013

Website

Venture Leaders China

The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.

Venture Leaders China 2018

Website